Login to Your Account



Clinic Roundup


Friday, September 14, 2012

• Generex Biotechnology Corp., of Worcester, Mass., reported early results from a Phase II study of its AE37 vaccine in patients with HER2 low-expressing and triple-negative breast cancer, which showed an overall reduction of 42 percent in the risk of relapse in all patients in the study who received the vaccine, and a 66 percent reduction in the risk of relapse for patients with low expression of the HER2 oncoprotein who were classified as having triple-negative breast cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription